Posts

Leerink Partners Report Names Carterra a Core Enabler of the $7B 'Lab-in-the-Loop' Antibody Discovery Market

on

FDA panel strongly backs Moderna's mRNA flu vaccine for older adults, with final decision expected by early August 2026.

on

Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs

on

KOL Insight – Psoriatic Arthritis (Recent Trends, June 2026)

on

Outlook wins FDA appeal for twice‑rejected eye drug Lytenava, eyes June 2026 BLA resubmission

on

Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues

on

Makary’s FDA Reforms Continue to Advance Amid Leadership Turmoil

on

Bora snaps up MacroGenics' manufacturing, CDMO operations for up to $127.5M

on

CSL Takes $5B Impairment Charge and Revenue Cut

on

Amgen Announces Additional $300M Investment in Puerto Rico Manufacturing Facility

on

NervGen Pharma Appoints Keith Vendola as Chief Financial Officer

on

FDA's Vinay Prasad to Depart as Head of Vaccines and Biologics Division Amid Controversy

on

Pharma Industry's Reshoring Boom: Massive Investments Amid Tariff Pressures

on

CytomX Therapeutics Announces $250 Million Public Offering of Common Stock and Pre-Funded Warrants

on

Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board

on

Servier Acquires Day One Biopharmaceuticals for $2.5 Billion to Expand Rare Oncology Portfolio

on

Palvella Therapeutics Announces Pricing of Upsized Public Offering

on

Nkarta Reports Q3 2025 Financial Results: Cumulative Net Loss of $76.68 Million, EPS Beat Expectations

on

Sparrow Appoints Biopharmaceutical Veteran Carlo Incerti, M.D. to Board of Directors

on

MoonLake revives FDA push

on